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Abstract
Worldwide, canine mammary cancer (CMC) 
is the most frequent type of neoplasia in female 
dogs, and it is three times more frequent in dogs 
than in humans. In Colombia, CMC is the second 
most frequent type of cancer, after skin neoplasia. 
Genetics is one of the most important factors in-
volved in any type of cancer, and the genetic ba-
sis of this disease is reflected through line breed-
ing due to changes in allelic frequencies that are 
traceable using molecular markers. This study 
aimed to detect single nucleotide polymorphisms 
(SNPs) associated with CMC in blood samples 
collected from collected from healthy and CMC 
female dogs at Diego Villegas Toro Veterinary 
Hospital of Universidad de Caldas (Manizales, 
Colombia). We designed primers using Primer-
BLAST and Primer3, and gene fragments from 
HER2, MUC1, ESR1, and BRCA1 were amplified 
to identify SNPs through genome mapping using 
the UCSC Genome Institute genome browser. 
We used the genome of Canis lupus familaris Boxer 
breed [GCF_000002285.3, (CanFam 3.1)] as a refer-
ence to compare the gene fragments and SNPs. 
We associated SNPs with the CMC and control 
groups by testing odds ratios (OR) through Fish-
er’s exact tests to determine an association or risk 
for CMC. We detected two SNPs for ESR1, three 
for MUC1, six for HER2, and one for BRCA1. 
MUC1 was the only gene to display an SNP in 
an exonic region that resulted in an amino acid 
substitution (Pro>Thr). No significant differences 
based on the OR were found, though the majority 
of SNPs, with the exception of four, were found 
in females with CMC. We report a novel molecu-
lar marker for HER2 that amplifies exons 25–26 
and introns 24–25, and highlight the importance 
of conducting further studies on MUC1 and elu-
cidating the role of introns and splicing in candi-
date genes associated with CMC. 
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Introduction
Canine mammary cancer (CMC) is 
the most frequent group of neoplasia in 
female dogs, with a 50% to 70% incidence 
compared to other types of cancer; it is 
also three times more prevalent in dogs 
than in humans (Beselga, 2013; do Carmo 
Silva et al., 2019). In Colombia, CMC 
shows a 21.5% incidence and is second 
only to skin neoplasia (Caicedo and 
Acosta, 2012). In Manizales, 25% of all 
diagnosed cases of mammary neoplasia 
are malignant (Pedraza-Ordόñez et al., 
2008). 
The risk factors, harmful 
environments, and types and subtypes 
of CMC have been reported (Araújo et 
al., 2018). Genetics is one of the most 
important factors involved in any type of 
cancer, and is mainly manifested through 
linebreeding or in dog breeds that are 
highly susceptible to this disease (Borge 
et al., 2011). Line breeding causes changes 
in the allelic frequencies of regulatory 
genes involved in cancer, which can be 
studied through genomic markers. They 
are related to specific changes, such as 
single nucleotide polymorphisms (SNPs) 
(Wang and Moult, 2001). SNPs have been 
associated with changes in hormonal, 
epidermal, growth, cell differentiation, 
and cell cycle factors (Ressel et al., 2013; 
Campos et al., 2015; Hermo et al., 2017). 
Previous studies on dog breeds, genotype 
frequency and susceptibility to similar 
diseases provide efficient models to 
study the effects of different genes (Borge 
et al., 2011; Borge et al., 2013). These 
models imply using direct lines and their 
progeny, which can be easily studied 
by non-invasive genotyping through 
skin or fur scraping and blood samples 
(Siravegna and Bardelli, 2014). 
CMC is poorly characterized at the 
genomic level, unlike human breast 
cancer. This is evidenced by the low 
number of SNPs reported for different 
genes of interest showing genetic 
mutations and variations of medical 
importance (Liu et al., 2014). The main 
molecular markers and genes reported 
to date for CMC include estrogen 
receptors (ESR1), progesterone (PR), 
epidermal growth (HER2), hormone 
metabolism [cytochrome P450 (CYP1A1 
and CYP1B1)], cellular proliferation 
[proliferating cell nuclear antigen 
(PCNA)], cellular regulation [breast 
cancer 1 and 2 (BRCA1 and BRCA2)], 
apoptosis [ADP-ribose polymerase 
(PARP), caspases], and basal [mucin 1 
(MUC1) ], among others (Vinothini et 
al., 2009; Dawood et al., 2011). Many of 
these genes have important functions in 
the sustainment of cellular and molecular 
mechanisms (Borge et al., 2011). Medical 
diagnosis and the search for molecular 
markers directly associated with diseases 
and susceptible genotypes have greatly 
improved, given the advances in genomic 
studies (Ginsburg and Willard, 2009; 
Santillán-Garzón et al., 2015).
The human epidermal growth 
factor receptor 2 (HER2), also known 
as erb-b2 (receptor tyrosine kinase 2), is 
widely used as a molecular marker for 
mammary cancer prognosis in dogs and 
humans (Muhammadnejad et al., 2012). 
Furthermore, SNPs of HER2 related to 
CMC have been reported (Hsu et al., 2009; 
Canadas-Sousa et al., 2019a). Likewise, 
BRCA1 is used as a diagnostic molecular 
marker and is directly associated with 
tumour suppression and cell cycle 
regulation (Tsuchida Complete et al., 
2001; Rivera et al., 2009; Enginler et al., 
2014; Sun et al., 2015). Other molecular 
markers, such as estrogen receptor 
alpha (ESR1), are mediators of hormonal 
processes and can promote carcinogenic 
responses (Russo and Russo, 2008). 
Therefore, the direct relationship of 
these genes with regulatory mechanisms 
in mammary tissue has motivated the 
study of SNPs associated with CMC 
(Borge et al., 2013; Akis et al., 2019). 
MUC1 is involved in apoptotic responses 
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in tumour cells (Yin et al., 2003) and is 
considered a carcinogenic gene related 
to breast cancer in humans (De Cremoux 
et al., 2000; Kufe, 2013).
Several studies on SNP identification 
report mutations that can cause 
significant alterations in cellular function 
of candidate genes and, thus, could be 
used as molecular markers for cancer 
prognosis or diagnosis. This study aimed 
to detect SNPs of HER2, MUC1, ESR1, 
and BRCA1 genes in patients with CMC 
in Manizales (Caldas, Colombia). 
Materials and methods
Sample collection
We studied 31 cases of female dogs at 
Diego Villegas Toro Veterinary Hospital 
of Universidad de Caldas (Manizales, 
Colombia) between June 2018 and January 
2019. Nineteen patients showed alterations 
in mammary glands and 12 were healthy 
patients (control group). We collected 4 
mL of peripheral blood from each patient 
in 5 mL heparin tubes through aseptic 
venipuncture and immediately conserved 
the samples at -4 °C. 
Amplification of HER2, MUC1, ESR1, 
and BRCA1
Genomic DNA was isolated from 
blood samples using the DNeasy Blood 
and Tissue Kit (Qiagen®) following the 
manufacturer’s instructions. We assessed 
DNA quality by 1% agarose gel electro-
phoresis and estimated the amount of 
DNA through fluorometric quantifica-
tion on a Quantus Fluorometer™ (Pro-
mega®) using the QuantiFluor® dsDNA 
System (Promega®).
We searched the literature for primers 
used to analyse polymorphic sites in 
MUC1, ESR1, and BRCA1 (Table 1). 
For HER2, we designed primers using 
Primer-BLAST and Primer3 (Untergasser 
et al., 2012; Ye et al., 2012) and analysed 
the primers using Oligoanalyzer (IDT 
Integrated DNA Technologies). Primers 
were evaluated with conventional PCR 
on a Techne TC-PLUS thermocycler. We 
used a final volume per reaction of 40 μL, 
containing 20.6 μL ultrapure water, 8 μL 
5X buffer, 2.4 μL MgCl2 (25 mM), 3.2 μL 
dNTPs mix (10 mM), 0.6 μL each primer 
(25 μM), 2 units GoTaq® Flexi DNA 
Polymerase (Promega®), and 4 μL DNA. 
The thermal cycling conditions were 
initial denaturation at 95 °C for 5 min, 
followed by 35 cycles at 95 °C for 20s, 55 °C 
for 15s, 72 °C for 30s, and a final extension 
at 72 °C for 7 min. PCR products were 
separated by horizontal electrophoresis 
on 1% agarose gels using TBE 1X pH 8.0 
running buffer at 100v/40mA. Gels were 
stained with SYBR® Safe and visualized 
on a Gel Doc-It2 310 photodocumenter 
(UVP). Amplicons were purified using 























(Qiu & Lin, 
2016)
ESR1 F 5’-ACCACTCTTCACTGCCACTAACTC-3’ R 5’-TACTCTTTCCCCTGTCTTCCTAAT-3’ 55 °C 320 Intron 6
(Pathirana 
et al., 2010)
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the Wizard® SV Gel and PCR Clean-
Up System (Promega®), according to 
the manufacturer’s instructions. Sanger 
sequencing of the purified amplicons was 
provided by Macrogen (South Korea). 
Sequence quality was assessed using 
Geneious Trial v8.14 (Drummond et al., 
2009 and GeneStudio V.2.2 (GeneStudio 
Inc, 2011).
Identity, specificity, and genetic 
mapping of SNPs
The reference gene sequences for 
HER2, MUC1, ESR1, and BRCA1 were 
obtained from the genome of Canis lupus 
familaris Boxer breed [GCF_000002285.3, 
(CanFam 3.1)]. We mapped each gene to 
the genome using the BLAT tool (Kent, 
2002) of the UCSC Genome Institute 
genome browser (https://genome.ucsc.
edu/) (Karolchik et al., 2003) to compare 
SNPs and confirm their location and 
identity. Genomic locations and reference 
sequences for each gene are shown in 
Table 2. The sequences generated in 
this study were aligned to the reference 
sequences using ClustalW in MEGA X 
(Kumar et al., 2018).
Data analysis
To determine significant differences 
between the SNPs and tumour presence, 
we associated SNPs with the CMC and 
control groups by testing odds ratios 
(OR) using Fisher’s exact tests. We used 
a statistical significance level of 0.05. The 
analyses were conducted using IBM SPSS 
(Arbuckle, 2011).
Results
Of the 31 patients included in the 
study, 51.6% were purebred (e.g., Boston 
Terrier, English Bulldog, Border Collie, 
French Poodle, Labrador Retriever, 
Pinscher, Pitbull, Samoyed, Schnauzer, 
and Shih Tzu) and 48.4% were mixed-
breed. The DNA sequences obtained for 
each patient were compared to ESR1, 
MUC1, HER2, and BRCA1 reference gene 
sequences from the genome of Canis lupus 
familiaris Boxer breed [GCF_000002285.3, 
(CanFam 3.1)]. The alignments showed 
identities equal to or greater than 99%. 
Furthermore, we detected two SNPs for 
ESR1, three of MUC1, six of HER2, and 
one for BRCA1, as well as two deletions 
for MUC1 and three deletions of ESR1 
(Table 3). The GenBank accessions for 
the nucleotide sequences obtained in 
this study are [MT552115-MT552145] for 
HER2, [MT550815-MT550843] for ESR1, 
[MT561299-MT561329] for BRCA1, and 
[MT571366-MT571396] for MUC1.
The association analysis of SNPs with 
CMC and control patients did not show 
significant differences for any SNP. The 
OR did not indicate a direct significant 
Table 2. Candidate genes for SNP detection and genomic locations using the reference genome of 
Canis lupus familiaris [GCF_000002285.3 (CanFam 3.1)].
Gen 





ESR1 1 42081969-42368544 10 NC_006583.3 [403640] Estrogen receptor alpha




MUC1 7 42340375-42344690 8 NC_006589.3 [448784] Mucin 1
BRCA1 9 19958941-20025494 22 NC_006591.3 [403437]
Breast cancer type 
1 susceptibility 
protein
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association with CMC since only three 
SNPs (4451 C>A MUC1, 23079 T>G HER2, 
67395 ESR1 T>C) were found within the 
risk interval (>1) (Table 4). However, the 
majority of SNPs, with the exception of 
four, were detected in female dogs with 
CMC.
Discussion
This study involves SNPs in exons 
25 and 26 of HER2 and identifies unique 
SNPs in introns 24 and 25. Previous 
studies have identified SNPs of HER2 
associated with CMC in exons 14-18 (Hsu 
et al., 2009) and 9, 13, 14, 16, 23, and 27 
(Borge et al., 2011). These results suggest 
that most SNPs of HER2 related to CMC 
are located along the gene and not in 
certain regions. For ESR1, we found 
two novel SNPs in intron 6, while prior 
studies have only assessed exons 2, 4, and 
8 in relation to CMC (Borge et al., 2011). 
Borge et al. (2013) and Canadas-Sousa et 
al. (2019b) genotyped and haplotyped 
HER2, finding extensive and strong 
relationships along the entire gene.
For BRCA1, we report one SNP in in-
tron 21. BRCA1 is one of the most studied 
genes in CMC. Previous studies analys-
ing exon 9, intron 8, 5′ UTR (Enginler et 
al., 2014), exon 22 (Borge et al., 2011), 5’ 
Table 3. Detected SNPs and indels and their location and group (CMC patient or control) in the study 














HER2 6 Intron 24 T/G 23009
Shitzu CMC
Pincher CMC
Intron 24 T/G 23078 French Poodle Control




Intron 25 C/G 23304 Boston Terrier CMC
Intron 25 G/C 23399 Boston Terrier CMC
Intron 25 C/G 23427 Boston Terrier CMC
MUC1 3 Intron 6 C/A 4243 Shitzu CMC Intron 6 -/G 4250
Intron 6 C/A 4301 Mixed-breed Control Intron 6 -/A 4263
Exon 7a G/C 4451 Mixed-breed CMC
ESR1 2 Intron 6 T/C 67395
Mixed-breed Control




Intron 6 C/G 67282 Mixed-breed CMC Intron 6 -/G 67588
Intron 6 -/A 67593
BRCA1 1 Intron 21 C/T 63970 Mixed-breed CMC
a non-synonymous SNP located in position 1 of the codon, amino acid substitution Pro>Thr in position 1415 of the 
protein.
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flanking region (Qiu and Lin 2016), and 
5’/ 3’ UTRs (Sun et al., 2015), and array 
genotyping studies on BRCA1 (Rivera 
et al., 2009) found strong associations 
with the incidence and development of 
CMC. Consequently, research on this 
gene requires studying a wide region for 
association analyses. For MUC1, there 
are no SNP association studies in CMC; 
therefore, this is the first study to charac-
terize SNPs of MUC1 in exon 7 and in-
tron 6 in CMC research. We report three 
SNPs for MUC1, specifically, one result-
ing in an amino acid substitution (4451 
G/C, Pro/Thr). Other studies have found 
a relationship between the expression of 
MUC1 and CMC (Campos et al., 2015), 
and associated SNPs in humans (Zeil-
linger et al., 2000; Yang et al., 2007). These 
previous findings suggest that this gene 
strongly influences molecular mecha-
nisms in CMC, which must be further 
studied in canine models. Finally, we 
report two deletions of MUC1 and three 
of ESR1 in intronic regions, which could 
be used to curate the sequences of the 





name Alelle CMC (%) Control (%) P-value OR (95%)
4451 MUC1
G 1 (5.3%) 0 (0%)
0.613 0.947 (0.852-1.053)
C 18 (94.7%) 12 (100%)
4243 MUC1
C 1 (5.3%) 0 (0%)
0.613 0.947 (0.852-1.053)
A 18 (94.7%) 12 (100%)
4301 MUC1
C 0 (0%) 1 (8.3%)
0.387 1.091 (0.920-1.294)
A 19 (100%) 11 (91.7%)
67282 ESR1
C 1 (5.3%) 0 (0%)
0.613 0.947 (0.852-1.053)
G 18 (94.7%) 12 (100%)
67395 ESR1
T 2 (10.5%) 2 (16.7%)
0.507 1.074 (0.798-1.444)
C 17(89.5%) 10 (83.3%)
23009 HER2
T 2 (10.5%) 0 (0%)
0.368 0.895 (0.767-1.044)
G 17 (89.5%) 12 (100%)
23078 HER2
T 0 (0%) 1 (8.3%)
0.387 1.091 (0.920-1.294)
G 19 (100%) 11 (91.7%)
23095 HER2
A 3 (15.8%) 0 (0%)
0.216 0.842 (0.693-1.023)
T 16 (84.2%) 12 (100%)
23304 HER2
C 1 (5.3%) 0 (0%)
0.613 0.947 (0.852-1.053)
G 18 (94.7%) 12 (100%)
23399 HER2
G 1 (5.3%) 0 (0%)
0.613 0.947 (0.852-1.053)
C 18 (94.7%) 12 (100%)
23427 HER2
C 1 (5.3%) 0 (0%)
0.613 0.947 (0.852-1.053)
G 18 (94.7%) 12 (100%)
63970 BRCA1
C 1 (5.3%) 0 (0%)
0.613 0.947 (0.852-1.053)
T 18 (94.7%) 12 (100%)
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corresponding genes in the reference ge-
nome of Canis lupus familaris Boxer breed 
[GCF_000002285.3, (CanFam 3.1)].
The main challenges of studying 
specific candidate genes involved 
in diseases include the information 
obtained from these genes and 
coverage; the latter is limited by the 
design of molecular markers and, 
therefore, restricts the information and 
relationships that can be found (Thomas 
et al., 2009). SNP association studies in 
CMC have focused on exonic regions 
since these show direct changes in amino 
acid composition (Borge et al., 2011; 
Goebel and Merner, 2017). However, 
intronic SNPs can induce excisions and 
alternative splicing, promote changes in 
RNA stability or structure that directly 
affect gene expression, interfere with the 
speed and accuracy of transcription and/
or translation, and alter protein folding 
(Canadas-Sousa et al., 2019a). Moreover, 
the use of any gene involved in the 
etiopathogenesis of a disease should be 
supported by a significant association at 
the population level and/or experimental 
demonstration (Wang and Moult, 2001). 
In this context, all SNPs detected in 
this study are novel, since the majority 
are located in intronic regions and these 
SNPs are not generally studied. However, 
studies on SNPs in intronic regions 
are relevant since induced changes in 
excisions, splicing, and gene expression 
can significantly alter the phenotype and 
influence cancer development (Hiratani 
et al., 2005; Law et al., 2007). Moreover, 
we report a new marker of HER2 that 
amplifies exons 25–26 and introns 24–25, 
which can be promising for future studies 
on CMC.
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Diljem svijeta, tumor mliječne žlijezde 
kuja (CMC) najčešća je skupina neoplazija 
kuja te je tri puta učestalija u pasa nego u 
ljudi. U Kolumbiji, CMC je bio druga najčešća 
vrsta tumora, nakon neoplazija na koži. 
Nadalje, genetika je jedan od najvažnijih 
čimbenika uključenih u bilo koju vrstu 
tumora, a genetska baza ove bolesti održava 
se kroz linijski uzgoj uslijed promjena alelnih 
frekvencija, koje se mogu pratiti preko 
molekularnih markera. Ova studija imala je za 
cilj detektirati polimorfizme jednog nukleotida 
(SNP-e) povezane s CMC-om u uzorcima krvi 
prikupljenih od kuja s CMC-om i zdravih kuja 
u veterinarskoj bolnici Diego Villegas Toro 
Sveučilišta Caldas (Manizales, Kolumbija). 
Dizajnirali smo početnice uporabom Primer-
BLAST i Primer3 te su fragmenti gena 
HER2, MUC1, ESR1 i BRCA1 pojačani za 
identifikaciju SNP-a preko mapiranja genoma 
uporabom preglednika genoma Instituta za 
genom Sveučilišta Santa Cruz u Kaliforniji 
(UCSC). Rabili smo genom Canis lupus familaris 
pasmine bokser [GCF_000002285.3, (CanFam 
3.1)] kao referencu za usporedbu fragmenata 
gena i SNP-a. Povezali smo SNP-e s CMC-om 
i kontrolnim skupinama testiranjem omjera 
izgleda (OR) pomoću Fisherovih egzaktnih 
testova za određivanje povezanosti ili rizika 
od CMC-a. Detektirali smo dva SNP-a za ESR1, 
tri za MUC1, šest za HER2 i jedan za BRCA1. 
MUC1 je bio jedini gen koji je pokazao SNP 
u regiji egzona što je rezultiralo supstitucijom 
aminokiseline (Pro>Thr). Nismo pronašli 
značajne razlike na temelju OR-a, premda je 
većina SNP-a, izuzev četiri, pronađena u kuja 
s CMC-om. Prijavljujemo novi molekularni 
marker za HER2 koji pojačava egzone 25 - 
26 i introne 24 – 25 te naglašavamo važnost 
provođenja dodatnih studija na MUC1, kao i 
pojašnjenja uloge introna i izrezivanja u gena 
kandidata poveznih s CMC-om. 
Ključne riječi: genetsko mapiranje, genetska 
varijacija, intron, neoplazija mliječnih žlijezda, 
povezanost s SNP-om
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